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“Books are not made to be believed, but to be subjected to inquiry. When we consider a 
book, we mustn't ask ourselves what it says but what it means.”  
 
 
"Because learning does not consist only of knowing what we must or we can do, but also of 
knowing what we could do and perhaps should not do.”  
 
-William of Baskerville 
“The name of the rose” by Umberto Eco 
  
  
  
ABSTRACT 
Biological differences between the sexes of a species, also known as sexual dimorphism, can 
be found throughout developmental, physiological and pathological processes. In human 
disease, sexual dimorphism can explain marked differences in disease susceptibility. 
Rheumatic diseases, such as systemic lupus erythematosus (SLE) and primary Sjögren’s 
syndrome (pSS), are chronic systemic autoimmune disorders that predominantly affect more 
women than men. Although many mechanisms have been put forward in order to explain 
this sex bias, the molecular underpinnings and their translation into disease phenotype are 
still not fully understood. Therefore, the aim of this thesis was to explore potential sex 
differences in genetic aspects that contribute to disease development, as well as to 
characterize clinical features that might exhibit a sexually dimorphic pattern. 
In Paper I, we studied the expression of genes associated with pSS at basal state in 
splenic immune cells from wild type mice. The analysis revealed minor differences between 
female and male murine cells. Similar findings were obtained when human B cells and 
monocytes were investigated. Although these results suggested potential intrinsic 
differences, the extent of the sexual dimorphism observed in gene expression of risk loci 
could not entirely explain the marked sex skew in disease susceptibility. 
To instead address differences in gene regulation rather than expression, in Paper II 
we examined whether single nucleotide polymorphisms (SNPs) associated with SLE and 
pSS could affect the gene expression in a sex-specific manner. The analysis resulted in 
identification of sex-specific expression quantitative loci (eQTLs) in human B cells. The 
study of sex-influenced eQTLs in other cell subtypes and in whole blood highlighted the 
context-dependent effect of these eQTLs. 
Since variation in gene regulation of risk loci among the sexes can lead to a 
heterogeneous disease phenotype, in Paper III, Paper IV and Paper V we aimed to identify 
relevant sex differences in the clinical presentation of incident pSS, prevalent pSS and 
prevalent SLE, respectively. Our analyses showed that, despite being less prone to systemic 
autoimmune disorders, men have a more severe disease phenotype, characterized by more 
organ manifestations, an enhanced serological profile and more critical long-term 
complications when compared to their female counterparts. 
In summary, our present work demonstrates the importance of sexual dimorphism in 
disease susceptibility and phenotype; also, it sheds light on possible molecular mechanisms 
that orchestrate the immune regulation of these complex disorders. Our results should raise 
awareness of relevant clinical sex differences that can aid in providing a tailored treatment to 
these patients. 
RESUMEN 
Las diferencias biológicas entre los sexos de una misma especie, también conocidas como 
dimorfismo sexual, influyen varios procesos biológicos. En humanos, el dimorfismo sexual 
es responsable de la marcada susceptibilidad para presentar alguna enfermedad o 
sintomatología. Las enfermedades reumatológicas son un exponente clásico del dimorfismo 
sexual. Las enfermedades reumatológicas, como el síndrome de Sjögren primario (SSp) y el 
lupus eritematoso sistémico (LES), son un grupo de padecimientos autoinmunes 
caracterizados por inflamación crónica y manifestaciones sistémicas, donde más del 90% de 
los pacientes son mujeres. Aunque ya se han propuesto algunos mecanismos 
fisiopatológicos, los procesos moleculares encargados del inicio de la enfermedad y las 
consecuencias de éstos a nivel clínico todavía no han sido completamente esclarecidos. Por 
tanto, esta tesis tuvo por objetivo estudiar aspectos genéticos que podrían contribuir al 
desarrollo de enfermedades reumatológicas de forma diferente entre los sexos; además de 
caracterizar e identificar manifestaciones clínicas que podrían afectar a los sexos con 
diferente frecuencia o severidad. 
En el Artículo I, investigamos la expresión basal de genes que están asociados con el 
desarrollo del SSp y LES. El estudio se realizó primero en ratones, de los cuales se 
obtuvieron células inmunes del bazo. Los niveles de expresión génica entre las hembras y 
los machos no fueron considerables. En células inmunes humanas, la diferencia en expresión 
de estos mismos genes tampoco fue significativa entre mujeres y hombres. 
Puesto que no encontramos diferencias notables en expresión génica, en el Artículo II 
examinamos si el dimorfismo sexual podría estar presente más en la regulación de la 
expresión de dichos genes. Para ello, analizamos si polimorfismos de nucleótido único 
(SNPs) serían capaces de influenciar la expresión de genes cercanos a estas mutaciones de 
forma diferente entre los sexos (eQTLs). El análisis reveló que, efectivamente, SNPs 
relacionados con SSp/LES actúan como eQTLs y son dependientes del sexo y del tipo de 
célula. 
Las diferencias en el genotipo pueden tener diferentes efectos en el fenotipo de la 
enfermedad. En los Artículos III-V, encontramos diferencias clínicas significativas entre 
mujeres y hombres con SSp o LES. En general, los hombres con SSp y LES presentaron 
síntomas más severos que las mujeres. 
El presente trabajo representa una aproximación a los mecanismos genéticos que 
difieren entre los sexos y podrían desencadenar un proceso autoinmune. Este estudio, 
además, muestra una imagen clínica distinta entre los sexos que podría servir para un mejor 
diagnóstico y manejo de las enfermedades reumatológicas.  
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1 Background 
 
1.1 Sexual dimorphism in human biology 
 
Since early fetal development, women and men show characteristics that make them 
different and, at the same time, define them individually1 2. Differences between the sexes, 
defined as human female XX and human male XY, are found throughout a person’s lifetime 
and are a quintessential part of their biological development, from an embryo until an elder. 
Sexual dimorphism, defined as systematic differences between the different sexes of 
the same species, permeates and influences the function of many tissues, organs and systems 
in the human body. The human brain shows a distinctive sex-specific gene expression and 
sex-specific splicing pattern3; pain perception is different between women and men4 and 
many studies have highlighted important sex differences in pharmacokinetics and 
pharmacodynamics5, hinting that sex-specific therapeutic interventions could be of great 
benefit and preferable6. Sex differences are present also in our later years: aging occurs 
differently between the sexes7; women and men live longer and shorter lives, respectively. 
Even the most common causes of death between women and men are different8. 
Sexual dimorphism is also important to consider when we try to understand 
susceptibility to develop certain diseases. Cancer9, cardiovascular disease10-13, bowel 
disease14, chronic lung diseases15, osteoporosis16, just to name a few, are diseases that are 
differentially represented between women and men. However, no other group of diseases are 
more heavily influenced by the sex of the individual than autoimmune diseases (AID)17. 
 
1.2 Sexual dimorphism in the human immune system 
 
The sex of an individual can greatly influence the function of the immune system. The 
sexual dimorphism in the immunological response might serve different purposes and may 
respond to sex-specific external (environmental) and internal (physiological) factors. In other 
words, the immune system is tailored to offer protection in a sex-specific manner, depending 
on the particular situation of the individual (e.g. pregnancy vs menopause). This entails that 
our defense system is dynamic and is, thus, sensitive to changes that are acquired or inherent 
to human physiology. Several differences between the female and male immune system 
have been previously described. The disparities can be found either in infection 
susceptibility, innate or adaptive immune responses.  
In terms of infection, men are more prone to develop bacterial18 19, viral20 and parasitic 
infections21 than women aged between puberty and menopause. The enhanced female 
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resistance to infection constitutes the evidence for asseverating that the female immune 
response is more robust and, therefore, able to clear out infections at a faster rate than males, 
the later exemplified in the significantly lower risk for women to develop sepsis22. 
Sex differences in infectious diseases can be partly explained by differences in the 
innate immune compartment. Innate immunity represents the first line of defense against 
foreign antigens predominantly through pathogen-associated microbial pattern recognition 
(PAMP), such as the Toll-like receptors (TLR). TLRs are able to sense bacterial and viral 
components and provoke the stimulation of the cell in order to eliminate the infection; in the 
context of autoimmunity, TLRs are essential for understanding disease pathogenesis because 
a sustained or exacerbated TLR stimulation can lead to an overproduction of 
proinflammatory mediators23 24.  Overall, many studies have highlighted the increased 
expression of genes from the TLR pathway and TLR7 in females as opposed to males25. For 
example, Berghöfer et al26 demonstrated that peripheral blood lymphocytes (PBL) from 
women produce higher amounts of IFN-a after stimulation with a TLR7 ligand. Similarly, 
Griesbeck et al27 showed that, upon TLR7 stimulation, human female pDCs produce higher 
amounts of IFN-a than their male counterpart. They suggest that this might be due to 
increased levels of IRF5 at basal state in females compared to males. The sex bias observed 
here is of great relevance, considering the association of augmented levels of type I 
interferon and female-preponderant systemic autoimmune diseases. 
On the other hand, immune cells from males exhibit a different profile. PBMCs from 
men produce less IFN-a after TLR7 stimulation; however, upon TLR9 stimulation, they 
produce higher levels of the anti-inflammatory cytokine IL-10 than their female 
counterparts28. Moreover, male neutrophils have higher levels of TLR4 and produce more 
TNF than female neutrophils both at basal state and after stimulation with LPS, a TLR4 
ligand29. The increased reactivity of male neutrophils to LPS and consequent increased 
secretion of proinflammatory cytokines could be a fair explanation for men’s increased risk 
for septic shock.  In mice, however, female neutrophils and macrophages have a higher 
phagocytic activity than in the males30 and female APCs are better at presenting peptides 
than male APCs31. 
Cell frequencies can also be influenced by the sex of the individual. Abdullah et al32 
and Gleeson et al33 reported higher numbers of NK cells in men, while Bouman et al34 
showed increased numbers of monocytes in men. Conversely, women are reported to have 
higher numbers of NK T cells35-37. In mice, type 2 innate lymphoid cells (ILC2) are reduced 
in female mice of an MS-prone model38.  
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The human adaptive immune system also shows many signs of sexual dimorphism. 
Regarding sex differences in cell counts, scarce studies report higher numbers of  T cells in 
women than men34, and more specifically, higher counts in the CD4+ subset and 
CD4+/CD8+ ratio39. This sex skew in T cell numbers is mirrored by differences in function, 
as reported by Zhang et al40, where CD4+ T cells from healthy women produced higher 
levels of IFN-g as well as tended to proliferate more than CD4+ T cells from men. They also 
showed that stimulated male CD4+ T cells had a greater tendency for IL-17A production 
instead. In accordance with the previous study, a microarray of activated human CD4+ and 
CD8+ T cells identified significant differences in expression profiles between female and 
male cells41. 
The B cell compartment seems to be comparable between the sexes42 43. However, the 
concentration of serum immunoglobulins (Ig) differs between the sexes. IgA values are 20% 
higher in men than in women whereas IgM and IgG values are significantly higher in 
women than men44. The more robust humoral response observed in women may account for 
the higher levels of circulating Ig, which is prominently seen e.g. after administering a 
vaccine. 
Response to vaccination differs between women and men45 46. As reviewed by Klein et 
al47, women almost invariably respond with a higher humoral response against common 
vaccines such as influenza and hepatitis. A study has evaluated vaccination dosages and 
determined that women 18 to 49 years old vaccinated with a full dose of the trivalent 
inactivated influenza vaccine (TIV) responded as well or greater than men of the same age 
when vaccinated with a half dose48. Although the sex-biased mechanism driving the 
vaccination effect is still not clear, Klein et al47 analyzed the difference in gene expression at 
different time points after yellow fever vaccination in a sex-specific fashion and identified 
that women significantly upregulate more TLR-associated genes that active the interferon 
pathway. Paradoxically, women presented a more severe 2009 H1N1 influenza infection 
than men49 50 and were more reluctant to receive the A/H1N1 vaccine51. 
Constitutional and functional differences between a female and male immune system 
are generally overseen when analyzing experimental and clinical data. In terms of 
physiopathology, these differences could explain marked differences in disease 
susceptibility. While men mount a lesser immune response and tend to have more recurrent 
infections, women’s greater immune responses put them at a higher risk for developing 
immunopathologies if homeostasis is not fully restored. 
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1.3 Sex bias in autoimmune disease susceptibility 
 
According to the American Autoimmune Related Diseases Association, Inc. (AARDA), 
there are 80-100 different AID and an additional 40 are suspected of having an autoimmune 
basis. The increased susceptibility for females to develop AID is a well-documented and 
established notion in the field17. With the exception of ankylosing spondylitis52, type I 
diabetes53 and psoriasis54 which exhibit a slightly higher frequency in men, the most 
commonly diagnosed AID show a marked female sex skew. 
Hashimoto’s thyroiditis, with an estimated female to male ratio of 10-20:1, leads the 
ranking of female-biased AID, followed closely by primary Sjögren’s syndrome (pSS, 20-
9:1) and systemic lupus erythematosus (SLE, 9:1). Most other common AID, such as 
multiple sclerosis (MS), rheumatoid arthritis (RA), dermatomyositis and myasthenia gravis 
(MG) exhibit a more modest ratio (2-3:1)55. 
Although women can be more commonly affected by AID, the onset and diagnosis of 
the disease can vary within this group. For example, pSS is usually diagnosed between 40 
and 50 years of age whereas SLE is diagnosed most commonly between 25-35 years of age. 
This suggests that AID have different pathophysiological mechanisms that might be driven 
by several biological factors e.g. sex hormones, which fluctuate along a woman’s lifespan. 
Actually, in childhood, where differences in sex hormone levels are not that striking, the 
female preponderance in rheumatic diseases is less than in adulthood56. This strongly 
suggests, then, a pivotal role of estrogen levels in disease onset. 
Interestingly, the reproductive state of a woman can also influence the outcome of the 
disease. During pregnancy, it is widely accepted that AID dominated by T cell responses 
remit, whereas autoantibody-mediated AID tend to worsen. For example, in MS57 and RA58 
the symptoms recede during pregnancy, although there can be an immediate flare post-
partum. In contrast, SLE manifestations worsen during pregnancy59 60 and there is an 
increased risk for transferal of disease-associated autoantibodies to the fetus, which may 
result in neonatal lupus with a potentially lethal cardiopathy61. 
 
1.4 Proposed mechanisms for female preponderance in AID 
 
Despite the great body of research in AID, the female sex skew remains virtually elusive. 
There has been a major effort to identify factors that might predispose and lead to the 
development of AID; however, the complexity and variability of these chronic inflammatory 
diseases62 pose a challenge when trying to find causalities. 
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Nevertheless, various mechanisms have been proposed in order to explain the higher 
frequency of AID in women. The major hypotheses are as follows, in no particular order of 
importance (Figure 1). 
Genetics and epigenetics: Genome wide association studies (GWAS) have shed light 
on the genes implicated in several female-biased AID, including SLE63-70, pSS71, RA72 73 and 
MS74 75. The studies show, not surprisingly, a dysregulation in immune-related genes in 
cases versus controls. Further elucidation of the cellular pathways in which these genes act 
and their genomic regulation could potentially explain the molecular mechanisms of these 
diseases. Also, sex differences in epigenetic regulation have been proposed76. These 
discrepancies might account for the enhanced hypomethylation of interferon genes observed 
in SLE patients in comparison with healthy controls76-78.  
 
 
Figure 1. Factors that can influence the development of autoimmune diseases. (1) Sex 
differences in the immune system at steady state. (2) Sex hormones. (3) Genetics. (4) X chromosome. 
(5) Epigenetics. (6) Environmental factors (e.g. viral infections). (7) Microbiota. 
 
X chromosome: For long, the X chromosome has been associated with the 
development of female-biased AID but, strikingly, is often disregarded in GWAS and other 
genetic studies. The human X chromosome contains many genes that are crucial for immune 
regulation, such as TLR7, TLR8, CD40L and FOXP3, among others. The link between AID 
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and the X chromosome could be explained through the double dosage effect, a consequence 
from an incomplete X-inactivation of the second X chromosome in women. It is believed 
that up to 15% of the genes in the second X chromosome escape inactivation, contributing 
thus to an overexpression of genes that are closely related to the immune system79. Not only 
are X chromosomes from AID patients more transcriptionally active80 but also having X-
chromosome aberrations can be associated with AID development. In women with SLE and 
pSS, the prevalence of trisomy X (47 XXX) is increased in comparison with healthy women. 
Similarly, Klinefelter’s syndrome (47 XXY) is overrepresented in men with SLE and pSS81 
82. Additionally, the X chromosome contains around 10% of the described microRNAs in 
the human genome, many of which have been associated with regulation of the immune 
response83-85. This entails that microRNA-mediated mechanisms might vary between women 
and men due to differential X chromosome expression.  
Sex hormones: The apparent opposite effects of estrogen and testosterone are believed 
to be a major factor for understanding the sex bias in AID. While estrogens are considered 
predominantly immunostimulatory86, testosterone has been related primarily to 
immunosuppression87. There’s a large body of evidence that demonstrates the close interplay 
of sex hormones and the immune system21 88 89. Firstly, all major immune cell subsets 
express receptors for estrogen90, represented by estrogen receptor alpha (ERa/ESR1) and 
estrogen receptor beta (ERb/ESR2), which means that they are sensitive to fluctuations in 
estrogen levels. Estrogen seems to have a dual effect: at high concentrations (e.g. pregnancy) 
estrogens inhibit the Th1 pro-inflammatory pathways and stimulates the Th2 anti-
inflammatory pathways; at low levels (e.g. menopause) estrogens stimulate the production of 
pro-inflammatory cytokines such as TNF-a and IL-1b. The complex immune regulation of 
estrogen can be achieved through the surface estrogen receptor or as a transcription factor 
via direct binding to estrogen response elements in the promotor region of many genes. As 
reviewed by Hughes91, progesterone may have a biphasic behavior. At low physiologic 
levels, progesterone might be able to promote IFN-a, a main driver of AID. However, at 
higher concentrations, progesterone may suppress Th1 and Th17 responses by inducing the 
production of anti-inflammatory molecules. Additionally, elevated levels of prolactin have 
been associated with AID and correlated with serositis and anemia in SLE patients92.  
Regarding the primary male sex hormone, testosterone, the vast majority of the studies 
agree that androgens exert an immunosuppressive role, which in turn, is beneficial for 
prevention of AID. Interestingly, a retrospective study showed that decreased levels of 
androgens due to hypogonadism can increase the risk for developing rheumatic disease, 
namely RA and SLE93. 
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Environmental factors: Exposure to different environmental factors between women 
and men have been put forward as an added factor for developing AID. These factors can 
range from infectious agents94, chemicals e.g. those found commonly in cosmetics95, drug 
exposure96 97; pesticides have been associated with development of autoantibodies98 and 
exposure to insecticides has been related to presence of anti-nuclear antibodies99 100. 
Barragan et al101have also found an association of exposure to organic solvents with 
autoimmune traits. Vitamin D has been implicated in the physiopathology of AID102 since 
lower concentrations of this immunosuppressive vitamin could render an individual more 
susceptible to develop AID103. The exposure to different environmental factors might follow 
a gender role pattern due to differing occupations and behaviors between women and men. 
This type of studies are hard to perform due to their retrospective nature and the limitations 
in terms of measuring exposure. 
 Microbiota: In recent years, the dysbiosis of the gut microbiota has garnered 
considerable attention due to its implication with the development of AID104. Many studies 
in mice have identified differences in bacterial species between females and males105-108. 
Although less progress has been done in humans, Davenport et al109 have used a GWAS 
approach to study the human gut microbiome. They found that several bacterial taxa showed 
a sex-specific distribution and that some of them were consistent throughout the year’s 
seasons. The link between sex-specific dysbiosis in humans and AID development is still to 
be clarified. 
 
1.5 SLE and pSS: prototypical female-biased systemic AID 
 
SLE is an AID characterized by multi-organ involvement, dysregulated autoantibody 
production110 and elevated levels of type I interferon111. The incidence and prevalence of 
SLE vary considerably among countries and ethnicities112. In Sweden, for instance, the 
incidence is 4.8 cases per 100,000 inhabitants/year113, while prevalence ranges from 79-144 
per 100,000 in women and 12-25 per 100,000 in men114. 
SLE diagnosis is attained based on specific classification criteria. Currently, the most 
widely used diagnosis scheme is the 1982 American College of Rheumatology (ACR) 
classification criteria115. Briefly, the ACR criteria include 11 different domains: malar rash, 
discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal disorder, neurologic 
disorder, hematologic disorder, immunologic disorder and antinuclear antibodies. SLE 
diagnosis is achieved when a case fulfills at least 4 out of these criteria. 
SLE is an insidious disease, with a heterogeneous course and spontaneous flare-ups. 
The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was developed to 
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assess disease activity and organ damage116. The SLEDAI scoring system considers 24 
different descriptors, each with their own score weight. Thus, the SLEDAI total value 
correlates positively with disease severity. The British Isles Lupus Assessment Group 
(BILAG) disease index117 is also commonly used and, in contrast with SLEDAI’s global 
disease score, this scheme distinguishes and reports manifestations in separate 
organs/systems: general, mucocutaneous, neurological, musculoskeletal, cardiorespiratory, 
vasculitis, renal and hematological. 
Among SLE organ manifestations, renal involvement stands out due to its association 
with increased morbidity and mortality in SLE patients118 119. Lupus nephritis (LN) can lead, 
after some years, to end-stage renal disease, a critical complication that affects between 10-
30% of the patients120. LN has a diverse etiology, but is mainly associated with deposition of 
immune complexes containing anti-dsDNA121 122 and/or anti-C1q antibodies123, as well as 
genetic factors124 125. 
Histological examination of lupus nephritis is of utmost importance for effective 
therapeutic intervention. For this purpose, a histopathological classification has been 
devised. Renal biopsies are studied for lupus nephritis diagnosis based on either the World 
Health Organization (WHO) criteria126 or the International Society of Nephrology/Renal 
Pathology Society(ISN/RPS)127. Lupus nephritis renal biopsies can be classified based on 
their mesangial, endothelial or epithelial patterns127. Also, a subset of SLE patients can also 
exhibit features of antiphospholipid syndrome, giving rise to a more severe form of renal 
involvement denominated antiphospholipid associated nephropathy (APLN)128 129. 
Another female-biased AID is pSS. pSS is a chronic systemic AID characterized by 
lymphocytic infiltration in exocrine glands, predominantly the salivary and lacrimal glands, 
resulting in a decrease in secretory function that leads to the hallmark symptoms of 
xerostomia (dry mouth) and xerophtalmia (dry eyes)130. 
pSS is considered the second most common systemic AID, after RA. It has been 
estimated that the prevalence of pSS ranges from 0.9 to 6 per 1,000 individuals131. Although 
not life threatening in its milder form, pSS can have a great negative impact on the quality of 
life of the patients and, in some instances, lead to severe systemic manifestations and 
lymphoma. 
Besides the ocular and oral symptomatology, patients with pSS can present with many 
types of autoantibodies in serum, which serve both as biomarkers for diagnosis and as 
potential drivers of pathogenesis. Anti-Sjögren’s-syndrome-related antigen A (SSA) and 
anti-Sjögren’s-syndrome-related antigen B (SSB) are the most commonly associated with 
pSS. However, patients can also have anti-nuclear antibodies (ANA), anti-mitochondrial 
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antibodies (AMA), anti-centromere antibodies, anti-smooth muscle antibodies, antibodies 
against cyclic citrullinated peptides (anti-CCP), antibodies against carbonic anhydrase, anti-
muscarinic receptor antibodies, rheumatoid factor (RF) and cryoglobulins132 133. 
Anti-SSA and anti-SSB, present in about 40%-80% of the patients, are the 
prototypical pSS autoantibodies and those most commonly used in clinical practice for 
patient classification. Anti-SSA, also known as anti-Ro (anti-Ro52 and anti-Ro60) are two 
antibodies that recognize a 52 kDa and a 60 kDa intracellular RNA-complex protein, 
respectively134. On the other hand, anti-SSB (anti-La) recognizes a 48 kDa ribonucleoprotein 
which is, in part, associated with the Ro particle (60 kDa Ro plus hY RNA)135. In 
consequence, anti-La antibodies are usually also found in sera containing anti-Ro60. 
Although the predilection for generating antibodies against these intracellular antigens 
is currently not well understood, a major effort has been done to define the function of these 
autoantigens. The protein Ro52, alternatively named TRIM21, is an E3 ligase that negatively 
regulates proinflammatory cytokine production by ubiquitinating transcription factors of the 
interferon regulated factor family136. Noteworthy, antibodies against Ro52 are detected in 
patients many years prior to diagnosis, suggesting a gradual and chronic development of the 
disease and hinting at a possible pathogenic role for the autoantibodies in terms of tissue 
damage137. 
The Ro60 protein, encoded by TROVE2, is part of a ribonucleoprotein complex that, 
similarly to La, recognizes short noncoding Y RNAs. Additionally, Ro60 binds an RNA 
motif derived from endogenous Alu retroelements (retrotransposons). Alu transcripts are 
induced after stimulation with type I interferon and promote the secretion of 
proinflammatory cytokines by human peripheral blood cells138. 
The La antigen is a protein associated with newly synthetized RNA polymerase III 
transcripts. Its role is to stabilize these transcripts from exonuclease digestion139. Antibodies 
against Ro antigens can be found independently from anti-La antibodies, but not the 
opposite, and there is thus a high concordance of anti-La with anti-Ro positivity140. 
As previously exposed, autoantibodies play an important role in pSS. Actually, 
antibody positivity has been associated with disease activity in pSS141. However, the 
presence of autoantibodies represents just a fraction of the whole pathological picture. When 
it comes to patient classification, many other elements come into play. The most widely used 
consensus from Vitali et al 142 takes into account several classification criteria for pSS 
diagnosis: subjective criteria (Item I: Ocular symptoms and Item II: Oral symptoms) and 
objective criteria (Item III: Ocular signs, Item IV: Histopathology, Item V: Salivary gland 
involvement and Item VI: Autoantibodies). 
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pSS diagnosis is attained when the patient presents with any four out of the six items, 
as long as either item IV or VI is positive or when three out of the four objective criteria are 
present. There are also directives for secondary Sjögren’s syndrome and exclusion criteria 
for SS. 
As is customary in systemic AID, pSS patients can present symptoms in organs other 
than the exocrine glands. Extraglandular manifestations (EGM) can range widely143 144 and 
are the basis for assessing the EULAR Sjögren’s syndrome disease activity index 
(ESSDAI)145. The ESSDAI covers different domains of organ involvement: constitutional 
(recurrent fever, night sweats, weight loss), lymphadenopathy/lymphoma (enlarged lymph 
nodes, splenomegaly, B-cell malignancies), glandular (swelling of major salivary glands), 
articular (arthritis, synovitis), cutaneous (erythema, vasculitis, purpura, ulcers), pulmonary 
(persistent cough, interstitial lung disease, shortness of breath), renal (interstitial nephritis), 
muscular (myositis), peripheral nervous system involvement (polyneuropathy, 
mononeuritis), central nervous system involvement (multiple sclerosis-like syndrome, 
cerebrovascular accident, seizures, myelitis, meningitis) and hematological (anemia, 
neutropenia, thrombopenia, auto-immune cytopenia). 
pSS belongs to the group of AID that is characterized by an exacerbation of the 
humoral response, leading to a chronic inflammatory state driven most likely by type I 
interferons146 and, in some cases, systemic organ dysfunction. Although these clinical 
features are shared between female and male patients, it is still to be determined whether 
there are significant differences in disease presentation between women and men affected by 
pSS.  
 
1.6 Sex differences in clinical presentation of AID 
 
The sexual dimorphism observed in AID susceptibility extends likewise to the clinical 
presentation of the disease. Despite the overwhelming female preponderance, men suffering 
from AID have been repeatedly reported to have a more severe disease and a worse 
prognosis than their female counterparts. 
In SLE, men present more renal disease147-149, serositis148 150 and pleurisies148. Further, 
Andrade et al151  have identified male sex as a strong predictor for poorer long-term 
prognosis due to accelerated damage accrual while Manger et al152 reported male sex as a 
risk factor for increased SLE mortality. Male sex is also deemed in MS as a factor for 
accelerated disease progression153 and a significantly higher prevalence of comorbidities154 
such as diabetes, epilepsy, depression and anxiety. Although less clear, sex differences in 
RA severity and extraarticular manifestations have been also described, where women are 
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more frequently affected by keratoconjuctivitis sicca and men with rheumatoid nodules and 
lung disease155 156. 
Regarding pSS, several studies have addressed sex differences in clinical 
presentation157-164. As reviewed by Brandt et al165, some authors have identified differences 
in EGM and serological markers, with a focus on female prevalence. However, there’s no 
clear consensus on whether male sex is associated with a more severe disease. Interestingly, 
the first patient ever described with having symptoms suggestive of Sjögren’s syndrome was 
a 42-year-old man in 1892.
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2 Aims of the thesis 
 
Numerous studies have underlined the higher propensity for females to suffer from 
autoimmune disorders. The most striking sex differences are observed in rheumatic diseases, 
such as Sjögren’s syndrome, systemic lupus erythematosus, autoimmune thyroid disease and 
scleroderma. 
Even though the sexual dimorphism in systemic autoimmune disorders is broadly 
acknowledged, there is still a gap in understanding the underlying molecular mechanisms 
that drive it, as well as a comprehensive characterization of sex-specific features that could 
help with decision making in a clinical setting. Thus, this thesis aimed to: 
- Elucidate differences in the expression and regulation of genes associated with 
prominently sex-biased diseases such as primary Sjögren’s syndrome and systemic lupus 
erythematosus (Papers I and II). 
- Define differences in clinical and biomedical presentation of autoimmune disease in 
women and men, focusing on primary Sjögren’s syndrome and systemic lupus 
erythematosus (Papers III, IV and V).  
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3 Results and Discussion 
 
3.1 No striking sexual dimorphism in gene expression of pSS-associated risk loci at 
steady state  
 
Genetics are an integral contributor to the development of rheumatic diseases. Many large-
scale studies have identified single nucleotide polymorphisms (SNPs) in specific regions of 
the genome associated with immune regulation in systemic autoimmune diseases such as 
pSS and SLE. Although we have been able to pinpoint the genetic variations that may lead 
to disease, the molecular consequences of these variants are still being investigated.  
In the context of sexual dimorphism, one first approach would be to examine whether 
these genes associated with disease are constitutively expressed differently between the 
sexes; these variants could cause a downregulation or exacerbation of the constitutive gene 
expression and its subsequent role in immune function regulation. In Paper I, we therefore 
studied if the gene expression of established pSS risk loci is different in females and males at 
basal state. 
Our experiments consisted in assessing the gene expression by qPCR of Blk, Cxcr5, 
Fam167a, Il12a, Irf5, Stat4 and Tnip1, both in the whole organ (spleen) and in sorted 
CD19+ B cells, CD3+ T cells and CD11b+ monocytes from C57BL/6 wild-type mice. The 
whole-organ analysis did not reveal any sex-related differences in expression of the risk 
genes studied (Paper I, Figure 1). 
In order to account for cell heterogeneity in the whole spleen, we then performed the 
analysis in sorted immune cells. In the cell subset analysis, female splenic B cells showed a 
significantly increased expression of Stat4 (Paper I, Figure 2A), while male splenic T cells 
had an increased expression of Cxcr5 in comparison to their female counterparts (Paper I, 
Figure 2B). We did not identify a significant sex-dependent gene expression in splenic 
monocytes (Paper I, Figure 2C). 
We conducted an additional experiment in order to replicate our previous results. As 
shown in Figure 3, male splenic B cells showed a significantly higher expression of Cxcr5 
but not T cells as previously seen (Paper I, Figure 3A). The augmented Stat4 expression of 
female splenic T cells detected before was not replicated in this experiment (Paper I, Figure 
3A). To confirm the higher expression of Cxcr5 in male lymphocytes, another experiment 
was performed with purified CD19+ B cells and CD3+ T cells from spleens of 6 male and 6 
female mice (10-18 weeks old). The gene expression analysis confirmed a higher expression 
of Cxcr5 in male CD19+ B cells, while no difference in expression was observed for T cells 
(Paper I, Figure 3B).  
  15 
Taken together, our murine experiments revealed few instances where gene expression 
was significantly different between females and males. Of interest, Cxcr5 was consistently 
more expressed in male murine cells than in female cells. Polymorphisms in the CXCR5 
gene have been associated with the development of non-Hodgkin lymphoma, a severe 
complication observed in SLE and pSS and reported to be more common in male patients166.  
We hypothesized that the use of inbred, genetically homogeneous animals would 
allow us to identify more easily subtle differences in gene expression. Although we did find   
some, we also noted variation in gene expression across different experiments. This 
discrepancy could be explained by other factors unrelated to inherent sex differences in the 
genetic background, such as estrous cycle in the female mice or fighting in the male mice. 
Another reason could be technical variation that could mask existent minimal differences in 
expression. The apparent comparable basal state between female and male mice denotes 
that, regardless of sex, the homeostasis of the immune system is maintained and both groups 
are, in principle, capable of mounting a similar response.  
To expand our analysis, we investigated the expression of the same genes from a 
publically available dataset of sorted human CD19+ B cells and CD14+ monocytes167. 
Peripheral B cells from humans (Figure 2) did not show a marked sex-biased gene 
expression.  
 
 
 
 
 
 
 
 
Figure 2: Expression levels of pSS susceptibility genes in human CD19+ B cells. Expression levels of BLK, 
CXCR5, FAM167A, IL12A, IRF5, STAT4 and TNIP1 from sorted CD19+ B cells.  Results from 162 healthy 
women and 125 healthy men. Bars represent the mean expression of the risk loci in the specific group. The 
error bar indicates the standard error of the mean (SEM). Mann-Whitney U-test.  
 
BLK was the only significant gene that was slightly more expressed in female B cells. 
Human monocytes (Figure 3) from women showed a small increased expression of TNIP1 
when compared with monocytes from men. 
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Figure 3: Expression levels of pSS susceptibility genes in human CD14+ monocytes. Expression levels of 
BLK, CXCR5, FAM167A, IL12A, IRF5, STAT4 and TNIP1 from sorted CD14+ monocytes.  Results from 229 
healthy women and 185 healthy men. Bars represent the mean expression of the risk loci in the specific group. 
The error bar indicates the standard error of the mean (SEM). Mann-Whitney U-test.  
 
Contrary to the inbred mouse strains, the human population represents a broadly 
outbred group. Despite this stark contrast, the human immune cells still did not show a 
remarkable sexual dimorphic gene expression pattern, which in turn could be due to its 
genetic heterogeneity. These last results, however, reflect a fairer representation of the 
patient population and mirror the heterogeneity of systemic autoimmune disorders as well. 
Lastly, the comparable basal state gene expression between immune cells from women and 
men strengthens the notion that both sexes are equally equipped to respond; it’s the cascade 
of events originating from that response that differs between them. 
Although the analysis of steady-state gene expression was the scope of Paper I, it is 
worth noting that further studies will be needed to assess significant differences in gene 
expression upon stimulation. As many have reported before, female and male cells respond 
differently when immunologically challenged. The results shown here are from a healthy 
volunteer population, which means that the genetic background (and thus gene expression 
pattern) differs from disease-susceptible individuals. It would be informative to study how 
the variants associated with pSS have an impact on gene expression and if these variants 
affect the immune response differently between the sexes. This could be attained by studying 
samples from individuals carrying specific SNPs and then stimulating the cells to assess 
sexual dimorphic downstream effects. 
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3.2 SNPs associated with SLE and pSS influence the expression of neighboring genes 
in a sex-specific manner  
 
SNPs can have several effects with regard to gene expression and regulation168. One of those 
outcomes is expression quantitative trait loci (eQTLs). These eQTLs are SNPs that influence 
the expression of genes in the vicinity (cis-eQTLs) or farther away (trans-eQTLs) from the 
polymorphic site169. Many SNPs previously identified in pSS71 and SLE170 GWAS are 
eQTLs. These eQTLs are context dependent e.g. cell-specific167 and may be influenced by 
sex171 172. Considering sex as a variable in eQTL effects, in Paper II we therefore 
investigated whether SLE/pSS SNPs act as eQTLs in human CD19+ B cells in a sample of 
287 healthy volunteers (162 women and 125 men).  
The SNPs investigated, shown in Paper II Table 1, were chosen from the current 
literature of genetic association studies in SLE and/or pSS, with the criteria of reaching 
genome-wide significance (p<5.0*10-8) and being the first reported and/or top-associated 
SNP within the associated region, and/or being genotyped in the Fairfax et al. study167, from 
whom we kindly obtained genotype and expression data. 
Our analysis revealed significant sex-specific eQTLs in B cells. The most relevant 
findings are summarized in Paper II Table 3 and Paper II Figure 1, and a representative 
scheme is provided in Paper II Figure 2. The most significant eQTL effect difference 
between females and males was found for rs4637409 (proxy SNP for rs10516487 in the 
BANK1 locus) and the expression of SLC39A8. In females, presence of the SLE risk allele A 
was correlated with lower expression of SLC39A8, while the effect was opposite in males. 
The SLC39A8 (Solute carrier family 39 member 8) gene encodes a manganese and zinc 
transmembrane transporter localized mainly at the cell membrane, but also at the lysosomal 
and mitochondrial membranes173. SLC39A8 expression is under transcriptional control of the 
NFκB pathway. While its role in B cells has not been defined, it has been shown to be 
induced in other immune cells upon microbial challenge, leading to increased intracellular 
zinc levels174. In lung epithelium SLC39A8 was found to be essential for zinc-mediated 
protection against stress-induced cytotoxicity at the onset of inflammation175. Reduced 
expression of SLC39A8 in female carriers of the SLE-associated rs10516487 risk allele 
could potentially lead to enhanced inflammatory stress-induced cell damage and increased 
exposure of intracellular self-antigens.  
The CD74 gene encodes the class II invariant chain, and is well known for its function 
as a chaperone, which prevents binding of peptides to the MHC class II molecules in the 
endoplasmic reticulum (ER), promotes their exit from the ER, directing it into the  
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endocytic compartments, and contributes to peptide editing prior to antigen presentation176. 
CD74 has also been shown to be required for B cell maturation and function177, and plays an 
additional role as an accessory signaling molecule on the surface of antigen-presenting 
cells178. In the present study, we found decreased CD74 expression in B cells from females 
carrying the risk allele of rs10036748 (proxy SNP for the SLE and pSS associated 
rs7708392 in the TNIP1 locus), which functionally may relate to an altered regulation of the 
peptide repertoire presented by MHC II. In males, the same allele was associated with 
increased CD74 expression.  
Regarding functional consequences of the PXK region SNP, one study has reported 
that it influenced the rate of BCR internalization, and that subjects carrying the risk 
haplotype had a decreased rate of BCR internalization, a process known to impact B cell 
survival and cell fate179.  
Paper II described sex-specific eQTL effects of disease-relevant SNPs in human B 
cells. Previously, the importance of conducting eQTL analyses in defined cell subsets has 
been pointed out since these eQTLs can be context dependent. To evaluate if the sex-specific 
eQTLs were exclusive to B cells, we interrogated the same list of SNPs previously selected 
(Paper II, Table 1) in a dataset of sorted human CD14+ peripheral monocytes (414 healthy 
volunteers; 229 women and 185 men). Figure 4 is representative of our main findings in 
monocytes. 
                              
SNP Gene region Gene name p value FDR ß value 
rs922483 BLK/FAM167A FDFT1 0.0003 0.11 -0.12 
Figure 4. Top (most significant) sex-specific eQTL identified in human CD14+ monocytes. Genotypic 
effects of the proxy SNP rs922483 (r2=1) for the pSS-associated rs2736345 (BLK/FAM167A locus) on 
expression of FDFT1. Genotype label represents the risk loci additive effect (0=homozygous for non-risk allele; 
2=homozygous for risk allele; NA= Not available). Red box plots represent female monocytes while blue box 
plots indicate male monocytes. 
 
 Interestingly, we indeed also found sex-specific eQTLs in monocytes; however, the 
top hits didn’t match or were less significant than the ones found in B cells (Paper II, 
Supplementary Table S3). The most significant eQTL gene was FDFT1, which encodes 
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for an enzyme involved in cholesterol biosynthesis. FDFT1 has been studied in the context 
of T2D and cardiovascular disease, where monocytes from patients with these diseases 
exhibit a dysregulation of lipid metabolism pathways180. In the C57BL/6.NOD-Aec1Aec2 
mouse pSS model, defects in fat metabolism and fat deposition in salivary glands have been 
associated with pSS pathology181 182. In humans, serum lipid disturbances have been 
identified in pSS patients, with overall significantly lower levels of total cholesterol and 
HDL when compared to non-pSS sicca controls183. Additionally, fatty cell infiltration in 
salivary glands from pSS patients has been described184, although its pathogenic role is still 
to be elucidated. According to our results, female individuals who have the risk allele have a 
modest reduction in expression of FDFT1 but significantly reduced when compared to male 
individuals. Further investigation shall clarify the role of lipid metabolism in exocrine gland 
dysfunction and pathogenesis, as recent studies have underlined the connection of a faulty 
immune metabolism with the development of AID185. 
Although pSS and SLE are driven primarily by processes pertaining to the adaptive 
immunity compartment, there’s increasing evidence suggesting a role for cells of the 
innate immunity in systemic inflammation. More specifically, neutrophils have garnered 
recent attention due to the role of NETs in the pathogenesis of SLE and various others 
autoimmune diseases186. Despite being uncommon, secondary autoimmune neutropenia 
can also be associated with other autoimmune diagnoses187. Importantly, neutrophils have 
been described as inducers of type I interferon production188 but, notably, as synthesizers 
and secretors of type I interferons189 and other proinflammatory products190 191. Taking into 
account that neutrophils are the most abundant cell type in circulation, that a recent study 
showed marked sex differences in gene expression192, their counts are higher in women 
than men193 and their pathogenic role in systemic autoimmunity, we further analyzed a 
dataset of sorted human neutrophils194 (100 healthy volunteers; 50 women and 50 men) in 
order to assess sex-specific eQTLs. 
As we expected, we were able to find sex-specific effects that were exclusive to 
neutrophils, and not present in the previous B cells and monocytes studies (Figure 5). The 
most significant sex-specific eQTL gene in neutrophils was AP2A2. AP2A2 encodes for an 
adaptor protein involved in clathrin-mediated endocytosis195. Neutrophils can be activated 
by circulating immune complexes and environmental stimuli196 197. This activation is 
prominently mediated by TLRs, both in the surface of the cell and in the endosomal 
compartment. Indeed, human neutrophils express TLR1 through TLR10, except TLR3198. 
Interestingly, a study has shown that neutrophils are able to express TLR9 both in the 
plasma membrane and in the endosomal network199. In the context of systemic 
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autoimmunity, TLR9 is of relevance since its sustained engagement is directly associated 
with production of IFN-α200 201 and an interferon signature is a hallmark for systemic 
autoimmunity.  
 
                   
SNP Gene region Gene name p value FDR ß value 
rs4963128 IRF7/PHRF1/KIAA1542 AP2A2 0.001 0.06 0.25 
Figure 5. Top (most significant) sex-specific eQTL identified in human CD16+ neutrophils. Genotypic 
effects of the SLE-associated rs4963128 (IRF7/PHRF1/KIAA1542 locus) on expression of AP2A2. Genotype 
label represents the risk loci additive effect (0=homozygous for non-risk allele; 2=homozygous for risk allele). 
Red box plots represent female neutrophils while blue box plots indicate male neutrophils. 
 
In order for endosomal TLRs to encounter its ligands, the uptaken stimuli must be 
transported by vesicular trafficking into the corresponding endosomal compartment. As 
shown above, the increased expression of A2P2 in female neutrophils which carry the risk 
SNP might hint at an enhanced vesicular trafficking, making TLR ligands, such as those 
for TLR9, more readily available and thus promoting a more robust neutrophil response, 
with the resulting proinflammatory effects. It is important to recognize that the sex-
specific eQTL analysis performed in neutrophils represents a small study. However, its 
results might have interesting implications in understanding the intricate cell interaction 
observed in complex systemic diseases. 
In summary, our results highlighted that SLE and pSS related SNPs have a wide 
effect as eQTLs in a cell-specific manner. Considering that these diseases are heavily sex 
biased and that these SNPs might coincide with already inherent sex-influenced eQTLs in 
the genome, we wondered if these sex-specific eQTLs could also be identified in less sex-
biased autoimmune disorders. Therefore, our initial B cell analysis also contemplated an 
evaluation of T1D SNPs in the same dataset, as the sex difference in this autoimmune 
disease is very small. The results (Paper II, Supplementary Table S4) revealed that the 
T1D SNPs examined only exhibited a modest sex-specific effect; none of them were as 
significant or had a comparable size effect as the pSS/SLE SNPs. 
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The variation in sex eQTLs across cell types and diseases hints at an equally 
complex molecular mechanism. The possible mechanism of action of local eQTLs has 
been reviewed by others169. When sex is considered as a variable, the effect of the eQTL 
can have various outcomes172. Strikingly, a given SNP can have an eQTL effect in 
opposite directions between women and men. This last scenario suggests a more complex 
molecular mechanism that is not yet fully understood. However, we would like to propose 
two modes of action for sex-specific eQTLs. 
When we consider the pSS/SLE SNPs that showed a significant sex-specific eQTL, 
most of them are located in non-coding or intergenic regions with regulatory activity. 
These polymorphisms could be responsible for repression or enhancement of gene 
expression by e.g. epigenetic regulation. Sex hormones, namely estrogen and testosterone, 
have DNA-binding capabilities and, thus, can act both as transcription factors and 
chromatin modifiers202. The recruitment of the regulatory machinery, due to epigenetic 
changes driven by the SNP, could have an amplifying effect on the genetic region 
neighboring the SNP. We hypothesize that this process might influence the expression of 
the genes in close proximity to the SNP on a sex-specific manner, based on the presence of 
sex hormones. 
Another mechanism to understand sex-specific eQTLs comprises sex differences in 
gene regulation downstream of the risk loci studied. The SNP could directly affect the 
regulation of the risk gene which, in turn, could lead to differences in the expression of 
nearby genes through a pathway that is differentially regulated between the sexes, most 
probably orchestrated by sex hormones. 
The mechanisms described above might represent an oversimplification of the 
intricate gene regulation that might be responsible for sex-specific eQTLs. It’s important 
to note that, although these two processes could happen simultaneously, there might be 
many more possibilities, SNPs, eQTLs and stimuli that could explain the development of 
complex diseases such as SLE and pSS. 
Lastly, the SNPs that have been identified in SLE and pSS GWAS represent 
susceptibility loci that are, most likely, particular to women, since they represent 90% of 
the studied population. This means that, although women and men might share genetic 
variants, there might also be variants that are specific to male patients that, due to low 
representation or exclusion in GWAS, are not being appropriately captured. While 
conducting sex-specific GWAS in heavily sex-biased diseases is essentially not feasible, 
some203 have proposed methodologies to address this. Sex-specific genetic susceptibility 
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might shed light on molecular differences that might explain the heterogeneity in disease 
presentation between women and men. 
 
3.3 Women and men with pSS present different clinical features at time of diagnosis  
 
If we observe differences in the genotypic regulation between the sexes, then it could be 
expected to also find variation in the phenotypical presentation of a disease between the 
sexes. In fact, many studies have underlined that, despite women being more susceptible to 
develop systemic AID, men often present the same disease in a more severe form. In the 
case of pSS, some studies have shown varied results when it comes to defining sex 
differences in clinical presentation of the disease. The lack of consensus prompted us to 
study our own well-characterized cohort of pSS patients collected in the Stockholm area 
during 5 years204. In Paper III, we assessed the clinical and immunological profile of 
incident cases of female and male pSS patients in a population-based cohort (199 patients; 
186 women and 13 men) to determine if the clinical and serological presentation of the 
disease differs between sexes, and replicated the findings in an independent cohort (377 
patients; 368 women and 9 men). 
In our exploratory Stockholm cohort, we did not identify significant differences in the 
presentation of glandular manifestations related to sicca symptoms (Paper III, Table 1). 
The major differences where observed in EGM, where men more often presented EGM; 
also, frequencies of pulmonary (interstitial lung disease) and cutaneous (vasculitis) 
manifestations were significantly higher in the male pSS group (Paper III, Table 2). 
After measuring autoantibody levels in patient sera by ELISA, our most significant 
serological finding was that SSA+ male patients had higher levels of anti-Ro52 than SSA+ 
female patients (Paper III, Figure 1). Notably, Ro52 antibodies have been associated with 
pulmonary disease, particularly interstitial lung disease and pulmonary fibrosis 205 206, which 
we also observed more frequently in men from our cohort. 
Although this finding can help explain the increased severity of the disease in men, the 
few sera available for analysis should be noted. Further studies of incident cases with larger 
sample sizes is needed to consolidate the serological difference between female and male 
patients. Serological investigations performed in previous studies of prevalent cases show 
considerable discrepancies between the frequencies of anti-Ro/SSA positivity among the 
male patients. The different observations may relate to the time point of serum sampling, as 
it is possible that more women develop higher autoantibody levels with disease progression. 
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The differences between studies could potentially also depend on the assay used for 
autoantibody testing and the presence of Ro60 and Ro52 antigens, respectively. 
In order to validate our findings, we analyzed a similar cohort of incident pSS cases 
from the Rheumatology Clinic in Pisa, Italy. Paper III, Table 4 recollects the features and 
EGM that significantly differed between female and male patients from the replication 
cohort, as well as the meta-analysis conducted to assess replicability of our results. 
Unfortunately, sera from the time of diagnosis were not available in this cohort. 
A strength of our investigation is that the studied exploration cohort was generated in a 
population-based manner representing approximately 95% of all incident cases in the 
specific geographical area during the five year-period during which the cohort was 
established204. By this approach, selection bias was avoided. Also, more than 90% of the 
patients were examined and diagnosed by the same clinician, diminishing variation in 
assessment procedures and evaluation204. An additional strength of the study is that an 
independent cohort of incident pSS was used to verify observations. Around 90% of patients 
were seen by one specific clinician also in this cohort. Noteworthy, the replication cohort 
was not population-based, potentially explaining some of the differences observed between 
the cohorts. The catchment and inclusion of patients in the replication cohort might have 
been more delayed than in the exploratory cohort, which could account for higher numbers 
of EGM. Despite this, men from the replication cohort still showed a more severe disease 
phenotype.   
More than nine out of ten patients with pSS are women, and an inherent weakness of 
studies of sex-differences of pSS is thus the smaller number of men in any given cohort. 
This is also the main drawback of the present study, despite including all cases in a densely 
populated defined geographical area during a five-year period and using a replication cohort. 
  
3.4 Sexual dimorphism in pSS after long-term follow-up  
 
Systemic inflammatory disorders often present a heterogeneous disease course throughout 
time. This means that the disease phenotype at diagnosis might significantly fluctuate due to 
spontaneous flares, comorbidities, treatment, disease duration, and so on. Since we observed 
important sex differences in the clinical presentation of pSS at time of diagnosis, in Paper 
IV we investigated if the frequencies of symptoms and manifestations notably differed 
between female and male pSS patients after many years of having their disease. Similar to 
Paper III, Paper IV assessed the occurrences of autoantibodies, clinical manifestations 
related to ESSDAI and other comorbidities common in pSS.  
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The data analyzed consisted of a large pSS cohort collected in several Scandinavian 
Rheumatology centers (DISSECT consortium). Our studied population comprised 899 
female patients and 68 male patients (Paper IV, Table 1). We identified significant sex 
differences in terms of serological parameters and frequencies of some organ involvement. 
Overall, men presented distinctively with more severe clinical complications and positivity 
for a broader autoantibody repertoire.  
Our serological investigation revealed that the humoral response between the sexes 
was different; particularly, men presented more often with La/SSB, Ro/SSA+La/SSB and 
ANA positivity (Paper IV, Table 2). This increased immune activity observed among the 
male patients is of special interest since in a healthy state, men mount a lower antibody 
response in comparison with women 45-47. Although the pathogenic effect of autoantibodies 
has not been clearly established, the presence of certain autoantibodies has been associated 
with organ manifestations. Noteworthy, SSA antibodies are related to pulmonary diseases 205 
206, an extraglandular manifestation we observed overrepresented in the male patients from 
our cohort. Further, a recent study proposed that anti-La/SSB antibodies are a risk factor 
associated with increased mortality in pSS patients207. Thus, even though the pathogenic role 
of pSS-associated autoantibodies remains unknown, seropositivity has a strong correlation 
with organ involvement and worse prognosis, supporting the conclusion that the disease 
course is more severe in male patients than in female patients.  
Taking advantage of the large sample size, we further analyzed whether seropositivity 
could be related to the age at diagnosis of the patients, an indirect approach for 
understanding the influence of sex hormones. Indeed, sex hormones have been studied in the 
context of pSS208; sex hormones have been suggested to influence the immune system, 
especially in terms of antibody production209. To evaluate whether the number or percentage 
of autoantibody positive individuals diagnosed was related to menopause (the most common 
period for pSS diagnosis), we further stratified the female and male patients with and 
without autoantibodies based on age at diagnosis (Paper IV, Figure 1). We observed an 
increasing number of autoantibody-positive women being diagnosed up to 60 years of age, 
and that at the same time, a steadily increasing number of autoantibody negative women 
receiving the diagnosis (Paper IV, Figure 1A). The male group displayed a comparable 
pattern (Paper IV, Figure 1B). Consistently, also when analyzed as percent autoantibody 
positive (Paper IV, Figure 1C), the trend was similar in both the female and male group. 
Already in the late thirties/early forties the percentage of autoantibody positive patients 
diagnosed with pSS started to decline and did so steadily until the mid-seventies. Very few 
males were diagnosed after the age of 75 (n=2), making the last point of the curve less 
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relevant to consider. Altogether, the data show a consistent higher percentage of 
autoantibody-positive men. Neither the female nor male group did show any obvious change 
specific for age 50 or 55, which is commonly used as a proxy for menopause. 
In relation to EGM and comorbidities, interstitial lung disease, lymphadenopathy and, 
notably, lymphoma were significantly more frequent in male patients (Paper IV, Table 3). 
When we characterized the malignancies diagnosed in the patients, we did not see significant 
differences between the sexes in regards to lymphoma classifications (Paper IV, Table 4). 
On the other hand, hypothyroidism was more common in female patients (Paper IV, Table 
3). It is well known that pSS patients have an increased risk for developing non-Hodgkin 
lymphoma210-214. Sex-specific risk for lymphoma development in patients with rheumatic 
disease has been seldom studied, mainly due to the inclusion of mostly female patients. 
Nevertheless, Ansell et al have reported a significantly higher incidence of lymphoma in 
male RA patients. Despite the increased association of autoimmune diseases and lymphoma 
in men215, earlier studies of sex differences in lymphoproliferative malignancies in pSS have 
not shown a clear sex-specific predominance216 217. In contrast, our present study is the 
largest pSS cohort to report a significantly increased risk for male patients to present 
lymphoma in comparison with female patients. This is in accordance with the results from a 
smaller patient sample from which an increased risk for men affected with pSS, SLE, RA 
and autoimmune hemolytic anemia to develop lymphoma was reported218. 
The studied cohort offers a valuable large group of clinically carefully characterized 
patients with pSS, allowing for analysis of parameters that differ between men and women 
affected by the syndrome. The long follow-up time is essential for identifying clinical 
manifestations at different time points of the disease course. However, the patients included 
in this cohort were mostly included at tertiary referral centers of university hospital clinics. 
A possible limitation of the study is that the study population might therefore not mirror the 
general pSS patient population and that the patients described in this study represent cases 
with an overall more severe disease phenotype, both female and male patients. A further 
possibility is that male patients with mild symptoms and less severe disease are less often 
referred, as the primary health care doctor may not be as likely to suspect Sjögren’s 
syndrome due to its rarity in men, resulting in only men with more severe disease being 
included in the study. As the evaluation of extraglandular manifestations was dependent on 
doctors’ clinical assessments and did not include specific laboratory or physiologic tests 
unless the patient had symptoms, it is also possible that subclinical extraglandular 
manifestations may have been missed. However, the mean number of extraglandular 
manifestations diagnosed did not differ significantly between centers, nor did the proportion 
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of men and women contributed. A further limitation is the lack of EULAR primary 
Sjögren’s syndrome disease activity (ESSDAI) and patient-reported (ESSPRI) indexes219 at 
diagnosis, as well as information on other common extraglandular manifestations such as 
neurological diseases. 
A common drawback when studying a patient population in a retrospective manner is 
that the observations may be biased due to, for example, disease duration. In other words, 
more severe EGM or comorbidities could be associated with a longer time of dealing with 
the disease, introducing a bias in the analysis that could potentially deviate the risk for a 
particular manifestation with time and not another variable of interest (e.g. sex). In our 
present cohort, we circumvented this issue by comparing the number of years from diagnosis 
to last year of follow-up. The comparable years in disease duration (Paper IV, Table 1) 
between female and male pSS patients allowed us to compare the two groups without 
recurring to any sort of correction such as Cox regression analysis. We can, therefore, assert 
our observations because time has been accounted for equally in both populations. 
 
3.5 Sex-specific clinical features in SLE and lupus nephritis  
 
Among sex-biased rheumatic diseases, SLE is the one where more work has been 
done in relation to sexual dimorphism in the clinical presentation of the disease. Men with 
SLE have been described to exhibit more serious systemic complications, namely serositis 
and nephritis. Lupus nephritis is a critical pathological process that may lead to increased 
mortality in these patients. In Paper V, we analyzed sex differences in diagnosis criteria 
fulfillment and further studied whether there were important sex differences in the 
pathological features of lupus nephritis.  
The group studied consisted of 1233 SLE patients (1065 women and 168 men) 
included in the Scandinavian DISSECT consortium cohort. The lupus nephritis investigation 
was conducted in a sub-cohort of the same patients, consisting of 907 patients (784 women 
and 123 men). After considering the frequencies of each diagnosis criterion, we observed 
that male patients were significantly more affected by serositis (Paper V, Table 2). The 
increased frequency of serositis in male SLE has been recognized in previous studies, where 
male sex has been identified as a risk factor for the development of pleuritis, but not 
pericarditis150 220 221 222. However, in our study, we found both pleuritis and pericarditis to be 
significantly more present in men.  
Although the male susceptibility for serositis is currently not well understood, genetic 
polymorphisms could partly account for it. One example of how this may occur is the SNP 
in CXCR3 rs34334103 described by Im et al223, which is associated with pleuritis only in 
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male SLE patients. The CXCR3 gene, situated on the X chromosome, encodes a chemokine 
receptor which interacts with CXCL9, CXCL10 and CXCL11. This SNP may disrupt the 
chemokine axis, promoting a potential increase in lymphocyte migration into target tissues. 
This process might be enhanced in male SLE patients carrying this SNP and, thus, promote 
inflammation of the pleurae. In general, men with rheumatic diseases present more 
frequently with pulmonary complications. For example, patients with rheumatoid arthritis 
can also present with extra-articular manifestations, such as pleuritis. Rheumatoid pleuritis is 
more common in male than female patients224. As shown in Papers III and IV, men with 
primary Sjögren’s syndrome also exhibit more frequently interstitial lung disease166 225. 
Thus, it appears that the lung is a specially affected organ in male patients with systemic 
autoimmunity. Further studies shall aim to clarify the possible pathophysiological 
mechanisms involved in this sexually dimorphic feature. 
Renal involvement was prominently more common in men with SLE, as reflected by 
higher frequencies of proteinuria, cellular casts and, most importantly, lupus nephritis 
(Paper V, Tables 2 & 3). Currently, there are no proposed molecular mechanisms to explain 
this male propensity to present with renal manifestations. It is of note, though, that men from 
our cohort had more immunological disturbances (Paper V, Table 2), a criterion including 
positivity for autoantibodies such as anti-dsDNA antibodies, which are known to be a strong 
risk factor for lupus nephritis, although the difference between men and women with the 
regard to this parameter did not reach statistical significance. This enhanced humoral 
response in the male group could exacerbate the inflammation occurring in the glomeruli, 
contributing to the shorter time for nephritis development and progression to end-stage renal 
disease observed in our cohort. Also, our study is the first to identify a clear tendency of men 
with SLE to present APS associated nephropathy, a more severe form when compared with 
other types of nephritis classifications (Paper V, Table 3). 
Overall, our studied cohort confirmed that men with SLE are more likely to develop 
lupus nephritis (Paper V, Figure 1), as well as expanded our knowledge on this 
complication by showing that men can be diagnosed with a more severe form of nephritis 
and are more prone to progress into end stage renal disease (Paper V, Figure 1). Since 
increased renal disease in male SLE is a quite established notion, one can’t automatically 
rule out a possible bias in disease exploration. Renal function assessment in serum and urine 
are easy methods and, most of all, virtually non-invasive. Consistent and continued renal 
monitoring, thus, should help in screening renal involvement equally in both sex groups. The 
fact that in our cohort we didn’t see sex differences in frequencies of renal biopsies 
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performed suggests that the procedure was made based on pathological suggestive findings 
rather than sex bias in clinical practice.  
Conversely, female patients presented more frequently with malar rash, 
photosensitivity, oral ulcers and arthritis (Paper V, Table 2). The higher susceptibility for 
skin manifestations could be partly due to the effect of hormones. Although infrequent, some 
women may develop dermatitis during their menses, a sensitization triggered by the 
increased levels of estrogen during the menstrual period226. Estrogen may play a crucial role 
in skin inflammation and flares in SLE and, therefore, have a more negative impact in 
women due to its higher concentration than in men.
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4 CONCLUSION AND FUTURE PERSPECTIVES 
 
Sexual dimorphism occurs in the susceptibility, prevalence, course and severity of many 
common diseases. Systemic autoimmune diseases, specifically pSS and SLE, stand out as 
conditions among those with the highest gender-related differences in prevalence. 
Unequivocally, every report distinguishes that female are more prone to the development of 
these diseases. Even though this fact is apparent, we still lack an answer as to why females 
are more affected; in fact, the area is underexplored, especially considering its impact. 
The results from our studies hereby exposed allow us to propose a model for sexual 
dimorphism in systemic autoimmune diseases (Figure 6).  
 
Figure 6: Sexual dimorphism in disease regulation and presentation of pSS and SLE. 
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The development of an AID is influenced by many factors. Although the exact 
magnitude of their contribution for disease pathogenesis remains elusive, some of these 
factors can act differently based on the sex of the individual e.g. differential gene regulation 
by sex-specific and cell-specific eQTLs. The combination of these intrinsic and extrinsic 
factors ultimately culminates in the triggering of an autoimmune process. Underlying sex 
differences in disease susceptibility also translate in to sex differences in disease phenotype, 
mainly in relation with severe systemic manifestations. In the case of pSS, sexual 
dimorphism can be observed more evidently at an early stage of the disease while these 
differences decrease at a later stage. 
It is noteworthy that our results provide a comparable disease phenotype between 
diseases. Men with pSS and SLE present a more severe phenotype, which might not be all 
too surprising due to the similarity and often overlap of these two diseases. On the other 
hand, this common background can be problematic when trying to understand the diversity 
in tissue and organ manifestations. Though pSS and SLE might share a strong genetic 
backdrop, many have suggested differences in their etiology (e.g. different viral infections) 
and some clinical features are fundamentally hallmarks of each disease. For example, while 
pSS is characterized by exocrine gland dysfunction and an increased risk for B cell 
malignancies, patients with pSS do not usually present with photosensitivity and serositis 
which are a stamp of SLE. Rather, the common genetic susceptibility may be responsible for 
promoting a generalized inflammatory environment that then influences different organs in 
varying degrees of severity. This reinforces the idea that the dysregulation observed in AID 
might not only be exclusive of the immune system, but also in the tissue-specific milieu 
where these cells are acting on. Further, this predilection for certain organs may be because 
susceptible tissues may themselves been under the influence of other factors that display a 
sexual dimorphic pattern, resulting in a sex-specific organ involvement.  
Although men with rheumatic diseases have been for long considered as having a 
more severe disease, our results raise questions about how we are approaching and handling 
this typical understudied group of patients. There are many reasons that we could take into 
account in order to explain this feature: sex bias in clinical evaluation, sex bias in healthcare 
attitudes, underdiagnosis of men with rheumatic diseases, to name a few. In spite of this, the 
biological evidence presented in this thesis sustains that organ involvement and 
deterioration, hematological malignancies and autoantibody positivity are more frequent in 
men, phenotypical traits which might not necessarily be associated with a delay in diagnosis 
but instead to an inherent immunologically suppressed state that, upon major dysregulation, 
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is not able to counteract the overwhelming effects of the autoimmune process and manifests 
more systemically than compared to women. 
This thesis aimed to improve our understanding of the molecular mechanisms that 
govern this sexual dimorphism. We could take advantage of this knowledge to envision sex-
specific therapies that might target sex-specific dysregulated genes or molecular pathways. 
Our findings would also be important for other biological fields and for clinical studies, 
where sex bias is often disregarded. Finally, a sex-specific approach to disease is a step 
further towards what is called the future of patient care: Precision Medicine. 
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